The use of 90Y-FAPI-46 radioligand therapy resulted in controlled disease progression in nearly half of a 30-person cohort largely comprised of patients with advanced sarcomas, according to new research presented at the 2024 Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting.
Can fibroblast activation protein (FAP)-targeted treatment have an impact in controlling disease progression with advanced sarcomas?
In new research, presented at the 2024 Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting, researchers reviewed data from 30 patients who were treated with 90Y-FAPI-46 radioligand therapy. According to the study, 77 percent of the cohort (23 patients) had sarcomas, 10 percent (3 patients) had advanced metastatic pancreatic cancer and the remaining four patients had prostate cancer, gastric cancer, squamous cell carcinoma and cholangiocarcinoma. The study authors noted a total of 77 treatment cycles with 90Y-FAPI-46 over a 3.5-year period.
Imaging control of disease was obtained in 44 percent of patients (10/23) assessed with RECIST (version 1.1) criteria and 50 percent of patients (10/20) evaluated via PERCIST guidelines, according to the study authors. They pointed out that 35 percent of the patients who achieved disease control as per RECIST criteria had sarcomas.
While adverse hematological events were reported in 60 percent of the cohort (18/30), the researchers noted that six patients (20 percent) had grade 3 adverse events that were all attributed to hematological toxicity. The study authors added that none of the patients in the cohort reached critical organ radiation dose levels during treatment with 90Y-FAPI-46.
“The results of our study have demonstrated good tolerance and promising efficacy, particularly in controlling disease progression in patients with advanced sarcoma,” noted Helena Lanzafame, M.D., who is affiliated with the Department of Nuclear Medicine at University Hospital Essen in Essen, Germany. “This indicates a specific benefit for this patient group, who often have limited treatment options due to the aggressive nature and poor prognosis associated with metastatic stage disease. 90Y-FAPI-46 radioligand therapy represents a promising approach for these patients, potentially improving survival rates and quality of life.”
Noting the modality’s enhanced visualization with imaging of sarcomas and malignant solid tumors, the study authors maintained the use of 90Y-FAPI-46 radioligand therapy may provide significant promise in precision imaging and treatment.
“FAP-targeted radioligand therapy represents a groundbreaking approach in cancer treatment. Its ability to selectively target electively to FAP-expressing cells and deliver localized radiation, minimizing off-target effects, has the potential to offer significant advantages over traditional therapies,” added Dr. Lanzafame.
Reference
1. Lanzafame H, Pabst K, Mavroeidi IA, et al. 90Y-FAPI-46 radioligand therapy for advanced-stage solid tumors: a retrospective cohort analysis. Presented at the 2024 Society of Nuclear Medicine and Molecular Imaging Annual Meeting, June 8-11, Toronto, Canada. Available at: https://www.xcdsystem.com/snmmi/program/10OD8Tq/index.cfm . Accessed June 8, 2024.
Radiology ‘Game-Changer’: FDA Approves PET Agent for Enhanced Detection of Coronary Artery Disease
September 28th 2024Offering higher diagnostic efficacy than SPECT imaging for coronary artery disease (CAD) detection, the PET myocardial perfusion imaging agent Flyrcado™ (flurpiridaz F 18, GE HealthCare) provides unit dose availability and effectiveness in imaging patients with high BMI.
Study for Emerging PET/CT Agent Reveals ‘New Standard’ for Detecting Clear Cell Renal Cell Carcinoma
September 11th 2024Results from a multicenter phase 3 trial showed that the PET/CT imaging agent (89Zr)Zr-girentuximab had an 85.5 percent mean sensitivity rate for the diagnosis of clear cell renal cell carcinoma.
Researchers Show Higher Breast Cancer Upstaging Rate with 18F-FAPI PET/CT
September 9th 2024The imaging agent 18F-FAPI PET/CT demonstrated greater than a 45 percent higher sensitivity rate in comparison to 18F-FDG PET/CT for the detection of axillary and extraaxillary regional lymph node metastases, according to a lesion-based analysis from a recent study.